Catalog Advanced Search

Search by Categories
Search in Packages
Search by Format
Search by Type
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Start
End
Search by Keyword
Sort By
  • The ASAM Alcohol Withdrawal Management Webinar Series – Complicated Withdrawal & Special Populations

    Product not yet rated Contains 3 Component(s), Includes Credits Includes a Live Web Event on 11/17/2020 at 12:00 PM (EST)

    The fifth and final of its series, this webinar will provide an overview of the The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management's recommendations around both complicated withdrawal and special populations.

    image


    The ASAM Alcohol Withdrawal Management Webinar Series – Complicated Withdrawal & Special Populations


    The webinar follows the ASAM Alcohol Withdrawal Management Fundamentals webinar, which intends to aid clinicians in their clinical decision making and management of patients experiencing alcohol withdrawal syndrome, as written in The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management.

    Aspects of management may need to be adjusted for patients with or at risk for complicated AWS, such as the development of alcohol withdrawal seizure or alcohol withdrawal delirium, alcohol-induced psychotic disorder, or resistant alcohol withdrawal. Special considerations should also be given to specific populations including patients with medical conditions, patients who take opioids, and patients who are pregnant. This webinar will provide an overview of the treatment recommendations around both complicated withdrawal and special populations.

    Session Information

    Date: Tuesday, November 17 2020

    Time: 12:00 pm ET / 11:00 am CT/ 9:00 am PT

    Speaker(s): Darius Rastegar, MD, FASAM

    Learning Objectives

    By completing this session, you will be able to:

    • 1. Summarize the guideline’s treatment recommendations around complicated withdrawal and discuss how they should be used in practice. 
    • 2. Identify the different types of complicated withdrawal and how management should be adjusted for each.
    • 3. Describe the different special populations and how management should be adjusted for each.

    Darius Rastegar, MD, FASAM

    Associate Professor of Medicine, Johns Hopkins University School of Medicine

    Dr. Rastegar is a general internist and addiction specialist at Johns Hopkins Bayview Medical Center.  He provides outpatient primary care with a focus on caring for patients with substance use disorders, inpatient consultantions and is the medical director for an inpatient unit for treatment of substance withdrawal. He is also the program director for the Johns Hopkins Addiction Medicine fellowship and the co-author of the ASAM Handbook of Addiction Medicine.

    ACCME Accredited with Commendation

    CME/CE Credits

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this internet live course for a maximum of 1 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    NAADAC, the Association for Addiction Professionals

    This activity has been approved by the American Society of Addiction Medicine, as a NAADAC Approved Education Provider, for educational credits. NAADAC Provider #295, ASAM is responsible for all aspects of the programming.

    California Association for Drug/Alcohol Educators (CAADE)

    This educational program is approved by CAADE: #CP40 999 1222

    California Association of DUI Treatment Centers (CADTP)

    This educational program is approved by CADTP: #205

    Continuing Education Credits (CEUs)

    Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.

    Maintenance of Certification (MOC)

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1 LLSA credit towards ABPM MOC Part II requirements.

    ABA Maintenance of Certification (MOC)

    This activity contributes to the CME component of the American Board of Anesthesiology’s redesigned Maintenance of Certification in Anesthesiology TM (MOCA®) program, known as MOCA 2.0®.

    ABP Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn a maximum of 1 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.

    ABIM Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    ABAM Transitional Maintenance of Certification (Tmoc)

    Successful completion of this activity can be used to satisfy the American Board of Addiction Medicine (ABAM) for Tmoc as credits towards ABAM LLSA Part II requirements.

    American Board of Psychiatry and Neurology (ABPN)

    Successful completion of this CME activity can be used to satisfy the American Board of Psychiatry and Neurology’s (ABPN) CME requirement for Maintenance of Certification program.

    Program Planning Committee, CME Committee, Medical Education Council (MEC)

    In accordance with disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all CME activities. These policies include resolving all possible conflicts of interest for the Planning Committees, CME Committee, MEC, and Faculty. All activity Planning Committee members and Faculty have disclosed relevant financial relationship information. The ASAM CME Committee has reviewed these disclosures and determined that the relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity. 

    ASAM CME Committee Reviewer

    Ed Salsitz, MD, DFASAM - No Financial Disclosures

    Faculty & Planning Committee Disclosures

    Lewis S. Nelson, MD, FASAM (Chair) – No Relevant Financial Disclosures

    Kurt Kleinschmidt, MD, FASAM – No Relevant Financial Disclosures

    Gerald E. Marti, MD, PhD – No Relevant Financial Disclosures

    Darius Rastegar, MD, FASAM – No Relevant Financial Disclosures

    Dazhe Cao, MD – No Relevant Financial Disclosures

    George Kolodner, MD, DLFAPA, FASAM – Does Disclose: Kolmac Outpatient Recovery Centers, Self, Employment, Ownership Interest (includes stock, stock options, patent or other intellectual property) Clinical Condition: Substance Use Disorder

    Michael F. Weaver, MD, DFASAM – No Relevant Financial Disclosures


  • Treatment of Opioid Use Disorder: Waiver Qualifying - University Center, MI - Friday, November 13, 2020

    Product not yet rated Contains 3 Component(s), Includes Credits Includes a Live In-Person Event on 11/13/2020 at 8:00 AM (EST)

    The ASAM Treatment of Opioid Use Disorder Course: Includes Waiver Qualifying Requirements covers treating opioid use disorder by using interactive, case-based learning to teach evidence-based practices.

    image

    Host: Michigan Opioid Collaborative

    Friday, November 13, 2020 | 8:00 am - 5:00 pm

    Saginaw Valley State University
    GS202
    7400 Bay Road
    University Center, MI 48710

    Overview

    Welcome to the ASAM Treatment of Opioid Use Disorder Course. This course covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine. ASAM is an approved provider by CSAT/SAMHSA of DATA 2000 training. 

    Getting Started

    Please log in to begin. If you do not know your password, or you have forgotten it, select "Forgot Password" and you will be emailed a link to reset your password. Once you have completed the live course, return here to claim CME for the course. If you have any questions, please contact education@ASAM.org.

    Learning Objectives 

    Module 1 

    1. Assess patients for the full spectrum of harmful opioid use including misuse and use disorders
    2. Describe the current epidemiologic trends in opioid misuse including overdose and use disorders
    3. Recall opioid use neurobiology as it applies to the development of an opioid use disorder and relapse risk
    4. Summarize the laws regulating office-based opioid treatment including the Drug Addiction Treatment Act of 2000 and the Comprehensive Addiction and Recovery Act of 2016
    5. Summarize the clinical pharmacology, efficacy and safety of methadone, buprenorphine and naltrexone in treating opioid use disorders

    Module 2

    1. Identify and assess patients who are appropriate for treatment with medications for an opioid use disorder in an office-based setting
    2. Describe procedures for setting up office systems to support medication prescribing for opioid use disorders
    3. Describe procedures for initiating, stabilizing, maintaining, monitoring and modifying treatment of patients on buprenorphine or naltrexone

    Module 3

    1. Summarize the assessment and management of patients with psychiatric and medical co-morbidities associated with opioid use disorders
    2. Describe unique issues of treating adolescents, young adults, pregnant and postpartum patients maintained on medications for opioid use disorders
    3. Summarize acute and chronic pain management strategies for patients with an opioid use disorder

    Overall

    Apply for a waiver to prescribe buprenorphine to patients with opioid use disorder

    Accreditation & Disclosures

    Date of Release: July 2015
    Approved Through: July 2023

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this live activity for a maximum of 8 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been designated as an approved CME Activity by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of 8 AMA PRA Category 1 Credit(s)™ to the CME requirement for Part II: Lifelong Learning and Self-Assessment.

    Disclosures

    In accordance with the disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the CME Committee, Planning Committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All CME Committee, Planning Committee and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the content of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

    ASAM Treatment of Opioid Use Disorder Course Program Planning Committee

    NameNature of Relevant Financial Relationship
    Dan Alford, MD, MPH, DFASAM, ChairNone
    Edwin Salsitz, MD, DFASAM, Curriculum DirectorNone
    Alta DeRoo, MD, FASAM, FACOGNone
    Soraya Azari, MDNone
    Jill Mattingly, DHSc, MMSc, PA-CNone
    Debra Newman, PA-C, MPAS, MPHCommercial Interest: AbbVie
    What was received: Honoraria
    Role: Expert faculty for CME activities
    Commercial Interest: Gilead
    What was received: Honoraria
    Role: Expert faculty for CME activities
    Mary McMasters, MD, DFASAMNone
    Yngvild K. Olsen, MD, MPH, DFASAMNone
    Shawn Ryan, MD, MBA, FASAMCommercial Interest: Crosswave 
    What was received: Stock 
    Role: Advisor
    Commercial Interest: Dynamicare
    What was received: Stock
    Role: Advisor
    Kristin Smith, DNP, FNP-C, AAHIVSNone
    Tricia E. Wright, MD, MS, FACOG, DFASAMNone

    ASAM CME Committee

    NameNature of Relevant Financial Relationship
    Catherine Friedman, MD, FAPA, DFASAM, ChairNone
    Catharina Armstrong, MD, MPHNone
    Subhadeep Barman, MD, FASAM, FAPANone
    Benjamin Bearnot, MD, MPH, FASAMCommercial Interest: Johnson and Johnson
    What was received: Common stock
    Role: None
    Commercial Interest: Baxter International
    What was received: Common stock
    Role: None
    Commercial Interest: Takeda Pharmaceuticals
    What was received: Common stock
    Role: none
    R. Jeffrey Goldsmith, MD, DLFAPA, DFASAMCommercial Interest: Alkermes
    What was received: Travel expenses
    Role: Speaker
    Zwaantje H. Hamming, FNP-C, CARN-APNone
    Herbert L. Malinoff, MD, FACP, DFASAM None
    Noel Ilogu, MD, MRCP, DFASAMNone
    Edwin A. Salsitz, MD, DFASAMNone
     ASAM Staff and Consultants
    Arlene C. Deverman, MA, CAE, CFRENone
    Sandy MetcalfeNone
    Kate M. BrundageNone

    ASAM Medical Education Council

    NameNature of Relevant Financial Relationship
    Peter Selby, MBBS, CCFP, FCFP, MHSc, DFASAM, ChairCommercial Interest: Johnson & Johnson; Novartis; Pfizer Inc.
    What was received: Received free/discounted materials for research studies through an open tender process
    Role: Research Studies
    Commercial Interest: Pfizer Inc. Global Research Awards for Nicotine Dependence (GRAND).
    What was received: Grant funds
    Role: Principal investigator on research study
    Commercial Interest: Johnson & Johnson E-NRT Advisory Board
    What was received: Consulting Fees
    Role: Consulting on Johnson & Johnson E-NRT Advisory Board
    Daniel P. Alford, MD, MPH, DFASAMNone
    Michael Fingerhood, MD, FACP, FASAMNone
    Catherine R. Friedman, MD, FAPA, DFASAMNone
    Adam J. Gordon, MD, MPH, FACP, DFASAMNone
    Miriam S. Komaromy, MD, FACP, DFASAMNone
    Edwin A. Salsitz, MD, DFASAMNone
    Brian Hurley, MD, MBA, DFASAMNone
    Mark A. Weiner, MD, FASAMNone
     ASAM Staff and ConsultantsNone
    Penny S. Mills, MBANone
    Arlene C. Deverman, MA, CAE, CFRENone
    Marcia Jackson, PhDNone
    Dawn C. PiotrowskiNone
    Molly S. MazukNone
    Alexandra (Alli) KrouseNone
    Jennifer L. ButchartCommercial Interest: Merck
    What was received: Spouse received stocks
    Role: Stockholder


    Target Audience

    1. Physicians, Nurse Practitioners, Clinical Nurse Specialists, and Physician Assistants who wish to obtain a waiver to prescribe buprenorphine in office-based treatment of opioid use disorder.
    2. Clinicians and healthcare team members working with physicians who prescribe buprenorphine in office-based treatment of opioid use disorder.

    How to Claim CME

    1. Fill out the survey by clicking the “Fill out Survey” button in the box titled “Complete Live Portion Evaluation” at the end of the training.
      Pro tip: Be sure to scroll down on all Likert Scale questions. There are answers that expand past the size of the survey window.
    2. Submit the evaluation. (The next box should activate and the evaluation box should turn green with a white check mark)
    3. Click the button “Claim Medical Credits” in the box titled “CME Certificate”
    4. Choose the type of credit (Physician or Non-physician) and click submit.
    5. Click the button “View/Print Certificate” to save or print your certificate
      Pro tip: If you ever lose your certificate, you can come back to the e-Learning Center and view it on your Transcript (found on Dashboard)

    How to Apply for a Waiver

    Physicians

    SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.

    Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.

    If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.

    Other Approved Prescribers

    Apply

    NPs and PAs who have completed the 24 hours of required training may seek to obtain a DATA 2000 waiver for up to 30 patients by completing the Waiver Notification Form. Effective February 27, 2017, SAMHSA will only accept electronic submissions of the NOI.

    NPs and PAs may send copies of their training certificates to infobuprenorphine@samhsa.hhs.govor fax them to 301.576.5237. These waiver applications are forwarded to the Drug Enforcement Administration (DEA), which will assign the NP or PA a special identification number. DEA regulations require this number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with the NP’s or PA’s regular DEA registration number.

    SAMHSA shall review waiver applications within 45 days of receipt. If approved, NPs and PAs will receive a letter via email that confirms their waiver and includes their prescribing identification number. 

    Qualify

    To qualify for a waiver to treat patients with Opioid Use Disorder, NPs and PAs must:

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain
    • Complete no less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD
    • If required by state law, supervision or working in collaboration with a qualifying physician to prescribe medications for the treatment of OUD may be required.

    Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat OUD before you apply for the waiver.  Some states may have overriding state legislation that will prevent NPs from prescribing these medications even if Federal law allows it.

    Overview of Legislation

    Physicians

    The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies training is necessary for physicians to obtain a waiver to engage in office‐based treatment of opioid use disorders using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, who is one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses.

    Nurse Practitioners & Physician Assistants

    On July 22, 2016, President Obama signed the Comprehensive Addiction and Recovery Act (CARA) into law. CARA authorizes qualified NPs and PAs to become waivered to prescribe buprenorphine in office-based settings for patients with Opioid Use Disorder (OUD) for a five-year period expiring in October 2021.    

    To qualify, NPs and PAs must: 

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain  
    • Complete not less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD  
    • If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD

    HHS' announcement on November 16, 2016, enables NPs and PAs to immediately begin taking the 24 hours of required training. For the full HHS announcement, click here.

    NPs and PAs can begin the training immediately by taking the 8-hour buprenorphine course ASAM currently offers or that other stakeholders offer (see below for more information). The remaining 16 hours will have to be completed with one training provider. ASAM is developing multiple 16-hour training course options and formats, including collaborations with:

    The ASAM Treatment of Opioid Use Disorder Course has been made available in part by an unrestricted educational grant from Indivior, Inc.

  • Treatment of Opioid Use Disorder: Waiver Qualifying - Jackson, MI - Monday, October 26, 2020

    Product not yet rated Contains 4 Component(s), Includes Credits Includes a Live In-Person Event on 10/26/2020 at 8:00 AM (EDT)

    The ASAM Treatment of Opioid Use Disorder Course covers treating opioid use disorder by using interactive, case-based learning to teach evidence-based practices.

    image

    Host: Michigan Opioid Collaborative

    Monday, October 26, 2020 | 8:00 am - 5:00 pm ET

    Henry Ford Allegiance Health Charles Anderson Building – Auditorium
    205 N. East Avenue
    Jackson, MI 49201

    Overview

    Welcome to the ASAM Treatment of Opioid Use Disorder Course. This course covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine. ASAM is an approved provider by CSAT/SAMHSA of DATA 2000 training. 

    Getting Started

    Please log in to begin. If you do not know your password, or you have forgotten it, select "Forgot Password" and you will be emailed a link to reset your password. Once you have completed the live course, return here to claim CME for the course. If you have any questions, please contact education@ASAM.org.

    Learning Objectives 

    Module 1 

    1. Assess patients for the full spectrum of harmful opioid use including misuse and use disorders
    2. Describe the current epidemiologic trends in opioid misuse including overdose and use disorders
    3. Recall opioid use neurobiology as it applies to the development of an opioid use disorder and relapse risk
    4. Summarize the laws regulating office-based opioid treatment including the Drug Addiction Treatment Act of 2000 and the Comprehensive Addiction and Recovery Act of 2016
    5. Summarize the clinical pharmacology, efficacy and safety of methadone, buprenorphine and naltrexone in treating opioid use disorders

    Module 2

    1. Identify and assess patients who are appropriate for treatment with medications for an opioid use disorder in an office-based setting
    2. Describe procedures for setting up office systems to support medication prescribing for opioid use disorders
    3. Describe procedures for initiating, stabilizing, maintaining, monitoring and modifying treatment of patients on buprenorphine or naltrexone

    Module 3

    1. Summarize the assessment and management of patients with psychiatric and medical co-morbidities associated with opioid use disorders
    2. Describe unique issues of treating adolescents, young adults, pregnant and postpartum patients maintained on medications for opioid use disorders
    3. Summarize acute and chronic pain management strategies for patients with an opioid use disorder

    Overall

    Apply for a waiver to prescribe buprenorphine to patients with opioid use disorder

    Target Audience

    1. Physicians, Nurse Practitioners, Physician Assistants, Certified Nurse Midwives, Certified Registered Nurse Anesthetists, and Clinical Nurse Specialists who wish to obtain a waiver to prescribe buprenorphine in an office-based setting for opioid use disorder.
    2. Clinicians and healthcare team members working with physicians who prescribe buprenorphine in office-based treatment of opioid use disorder.

    Cara Poland

    MD, MEd

    Cara Poland, MD, M.Ed was trained in internal medicine at St. Joseph Mercy Hospital in Ann Arbor, Michigan and in addiction medicine at Boston Medical Center in Boston, Massachusetts. She has an interest in education physicians and physicians-in-training to improve care for patients with substance abuse and alcohol disorders. She is interested in medical student curriculum development and assessment, student well-being and identifying ways to improve the process of medical training. She sits on the Board of Directors for the Red Project and multiple leadership boards of various professional societies such as the Midwest Society of General Internal Medicine and American Society of Addiction Medicine. She is currently a physician at Spectrum Health's Center for Integrative Medicine.

    Christopher Frank

    MD, PhD

    Dr. Frank earned his undergraduate degree at the University of Michigan and graduated from Johns Hopkins University School of Medicine with an M.D. and a Ph.D. in molecular biology. He completed his family medicine residency at the University of Wisconsin in a specialized program designed to prepare family physicians to work in rural communities. Prior to joining the University of Michigan Department of Family Medicine, he worked eight years as a full-scope family physician in a Health Professional Shortage Area in Washington State, and as the health officer/medical director of a local health department. He taught medical students and residents as a clinical assistant professor in the University of Washington Department of Family Medicine. He also chaired a broad coalition that developed a regional response to the opioid crisis, served on the Washington State Board of Health, and led an innovative program that required mandatory reporting of fatal and non-fatal overdoses so patients could be quickly enrolled in evidence-based treatment and prevention services. His clinical interests include comprehensive primary care, including obstetrics, prevention and treatment of opioid-use disorders, and medical education. He is a waivered buprenorphine prescriber and treats patients with a range of substance-use disorders, including women struggling with opioid-use disorders during pregnancy. In addition to working with individual patients, he has been a supervising physician within a nurse-managed MAT program, and has worked on system-changes to improve access to treatment for patients in acute care settings and the criminal justice system.

    ACCME Accredited with Commendation

    CME/CE Credits

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this live internet-based activity for a maximum of 8 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    NAADAC, the Association for Addiction Professionals

    This activity has been approved by the American Society of Addiction Medicine, as a NAADAC Approved Education Provider, for educational credits. NAADAC Provider #295, ASAM is responsible for all aspects of the programming.

    California Association for Drug/Alcohol Educators (CAADE)

    This educational program is approved by CAADE: #CP40 999 1222

    California Association of DUI Treatment Centers (CADTP)

    This educational program is approved by CADTP: #205

    Continuing Education Credits (CEUs)

    Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.

    Maintenance of Certification (MOC)

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 8 LLSA credit towards ABPM MOC Part II requirements.

    ABA Maintenance of Certification (MOC)

    This activity contributes to the CME component of the American Board of Anesthesiology’s redesigned Maintenance of Certification in Anesthesiology TM (MOCA®) program, known as MOCA 2.0®.

    ABP Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn a maximum of 8 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.

     ABIM Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    ABAM Transitional Maintenance of Certification (Tmoc)

    Successful completion of this activity can be used to satisfy the American Board of Addiction Medicine (ABAM) for Tmoc as credits towards ABAM LLSA Part II requirements.

    American Board of Psychiatry and Neurology (ABPN)

    Successful completion of this CME activity can be used to satisfy the American Board of Psychiatry and Neurology’s (ABPN) CME requirement for Maintenance of Certification program.

    Program Planning Committee, CME Committee, Medical Education Council (MEC), and Faculty Disclosure Information

    In accordance with disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all CME activities. These policies include resolving all possible conflicts of interest for the Planning Committees, CME Committee, MEC, and Faculty. All activity Planning Committee members and Faculty have disclosed relevant financial relationship information. The ASAM CME Committee has reviewed these disclosures and determined that the relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

    ASAM Treatment of Opioid Use Disorder Course Program Planning Committee

    NameNature of Relevant Financial Relationship
    Dan Alford, MD, MPH, DFASAM, ChairNone
    Edwin Salsitz, MD, DFASAM, Curriculum DirectorNone
    Alta DeRoo, MD, FASAM, FACOGNone
    Soraya Azari, MDNone
    Jill Mattingly, DHSc, MMSc, PA-CNone
    Debra Newman, PA-C, MPAS, MPHCommercial Interest: AbbVie
    What was received: Honoraria
    Role: Expert faculty for CME activities
    Commercial Interest: Gilead
    What was received: Honoraria
    Role: Expert faculty for CME activities
    Mary McMasters, MD, DFASAMNone
    Yngvild K. Olsen, MD, MPH, DFASAMNone
    Shawn Ryan, MD, MBA, FASAMCommercial Interest: Crosswave 
    What was received: Stock 
    Role: Advisor
    Commercial Interest: Dynamicare
    What was received: Stock
    Role: Advisor
    Kristin Smith, DNP, FNP-C, AAHIVSNone
    Tricia E. Wright, MD, MS, FACOG, DFASAMNone

    ASAM CME Committee

    NameNature of Relevant Financial Relationship
    Catherine Friedman, MD, FAPA, DFASAM, ChairNone
    Catharina Armstrong, MD, MPHNone
    Subhadeep Barman, MD, FASAM, FAPANone
    Benjamin Bearnot, MD, MPH, FASAMCommercial Interest: Johnson and Johnson
    What was received: Common stock
    Role: None
    Commercial Interest: Baxter International
    What was received: Common stock
    Role: None
    Commercial Interest: Takeda Pharmaceuticals
    What was received: Common stock
    Role: none
    R. Jeffrey Goldsmith, MD, DLFAPA, DFASAMCommercial Interest: Alkermes
    What was received: Travel expenses
    Role: Speaker
    Zwaantje H. Hamming, FNP-C, CARN-APNone
    Herbert L. Malinoff, MD, FACP, DFASAM None
    Noel Ilogu, MD, MRCP, DFASAMNone
    Edwin A. Salsitz, MD, DFASAMNone
     ASAM Staff and Consultants
    Arlene C. Deverman, MA, CAE, CFRENone
    Sandy MetcalfeNone
    Kate M. BrundageNone

    ASAM Medical Education Council


    NameNature of Relevant Financial Relationship
    Peter Selby, MBBS, CCFP, FCFP, MHSc, DFASAM, ChairCommercial Interest: Johnson & Johnson; Novartis; Pfizer Inc.
    What was received: Received free/discounted materials for research studies through an open tender process
    Role: Research Studies
    Commercial Interest: Pfizer Inc. Global Research Awards for Nicotine Dependence (GRAND).
    What was received: Grant funds
    Role: Principal investigator on research study
    Commercial Interest: Johnson & Johnson E-NRT Advisory Board
    What was received: Consulting Fees
    Role: Consulting on Johnson & Johnson E-NRT Advisory Board
    Daniel P. Alford, MD, MPH, DFASAMNone
    Michael Fingerhood, MD, FACP, FASAMNone
    Catherine R. Friedman, MD, FAPA, DFASAMNone
    Adam J. Gordon, MD, MPH, FACP, DFASAMNone
    Miriam S. Komaromy, MD, FACP, DFASAMNone
    Edwin A. Salsitz, MD, DFASAMNone
    Brian Hurley, MD, MBA, DFASAMNone
    Mark A. Weiner, MD, FASAMNone
     ASAM Staff and ConsultantsNone
    Penny S. Mills, MBANone
    Arlene C. Deverman, MA, CAE, CFRENone
    Marcia Jackson, PhDNone
    Dawn C. PiotrowskiNone
    Molly S. MazukNone
    Alexandra (Alli) KrouseNone
    Jennifer L. SilverCommercial Interest: Merck
    What was received: Spouse received stocks
    Role: Stockholder


    How to Claim CME

    1. Fill out the survey by clicking the “Fill out Survey” button in the box titled “Complete Live Portion Evaluation” at the end of the training.
      Pro tip: Be sure to scroll down on all Likert Scale questions. There are answers that expand past the size of the survey window.
    2. Submit the evaluation. (The next box should activate and the evaluation box should turn green with a white check mark)
    3. Click the button “Claim Medical Credits” in the box titled “CME Certificate”
    4. Choose the type of credit (Physician or Non-physician) and click submit.
    5. Click the button “View/Print Certificate” to save or print your certificate
      Pro tip: If you ever lose your certificate, you can come back to the e-Learning Center and view it on your Transcript (found on Dashboard)

    How to Apply for a Waiver

    Physicians

    SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.

    Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.

    If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.

    Other Approved Prescribers

    Apply

    NPs and PAs who have completed the 24 hours of required training may seek to obtain a DATA 2000 waiver for up to 30 patients by completing the Waiver Notification Form. Effective February 27, 2017, SAMHSA will only accept electronic submissions of the NOI.

    NPs and PAs may send copies of their training certificates to csatbupinfo@dsgonline.com. These waiver applications are forwarded to the Drug Enforcement Administration (DEA), which will assign the NP or PA a special identification number. DEA regulations require this number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with the NP’s or PA’s regular DEA registration number.

    SAMHSA shall review waiver applications within 45 days of receipt. If approved, NPs and PAs will receive a letter via email that confirms their waiver and includes their prescribing identification number. 

    Qualify

    To qualify for a waiver to treat patients with Opioid Use Disorder, NPs and PAs must:

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain
    • Complete no less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD
    • If required by state law, supervision or working in collaboration with a qualifying physician to prescribe medications for the treatment of OUD may be required.

    Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat OUD before you apply for the waiver.  Some states may have overriding state legislation that will prevent NPs from prescribing these medications even if Federal law allows it.

    Overview of Legislation

    Physicians

    The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies training is necessary for physicians to obtain a waiver to engage in office‐based treatment of opioid use disorders using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, who is one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses.

    Nurse Practitioners & Physician Assistants

    On July 22, 2016, President Obama signed the Comprehensive Addiction and Recovery Act (CARA) into law. CARA authorizes qualified NPs and PAs to become waivered to prescribe buprenorphine in office-based settings for patients with Opioid Use Disorder (OUD) for a five-year period expiring in October 2021.    

    To qualify, NPs and PAs must: 

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain  
    • Complete not less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD  
    • If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD

    HHS' announcement on November 16, 2016, enables NPs and PAs to immediately begin taking the 24 hours of required training. For the full HHS announcement, click here.

    NPs and PAs can begin the training immediately by taking the 8-hour buprenorphine course ASAM currently offers or that other stakeholders offer (see below for more information). The remaining 16 hours will have to be completed with one training provider. ASAM is developing multiple 16-hour training course options and formats, including collaborations with:

    The ASAM Treatment of Opioid Use Disorder Course has been made available in part by an unrestricted educational grant from Indivior, Inc.

  • The ASAM Alcohol Withdrawal Management Webinar Series - Pharmacotherapy

    Product not yet rated Contains 3 Component(s), Includes Credits Includes a Live Web Event on 10/20/2020 at 12:00 PM (EDT)

    The fourth of its series, this webinar will provide an overview of the The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management's recommendations around the appropriate use of pharmacotherapy for patients with AWS.

    image


    The ASAM Alcohol Withdrawal Management Webinar Series – Pharmacotherapy


    The webinar follows the ASAM Alcohol Withdrawal Management Fundamentals webinar, which intends to aid clinicians in their clinical decision making and management of patients experiencing alcohol withdrawal syndrome, as written in The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management.

    Appropriate pharmacotherapy for alcohol withdrawal is a balance of alleviating symptoms and normalizing signs of AWS while preventing the adverse effects associated with the medications being administered. This webinar will provide an overview of the recommendations around the appropriate use of pharmacotherapy for patients with AWS. 

    Session Information

    Date: Tuesday, October 20, 2020

    Time: 12:00 pm ET / 11:00 am CT/ 9:00 am PT

    Speaker(s): Michael F. Weaver, MD, FASAM

    Learning Objectives

    By completing this session, you will be able to:

    • 1. Summarize the guideline’s treatment recommendations around pharmacotherapy and discuss how they should be used in practice.  
    • 2. Recognize all medications that can be used to treat patients with AWS and explain the circumstances in which one form of medication is more effective than another.
    • 3. Understand the limitations and risks associated with the various medications used to treat patients with AWS.

    Michael Weaver

    MD, DFASAM

    Michael Weaver, MD, DFASAM is a Professor in the Department of Psychiatry and Medical Director of the Center for Neurobehavioral Research on Addictions (CNRA) at the McGovern Medical School at the University of Texas Health Science Center at Houston (UTHealth). He received his M.D. degree from Northeast Ohio Medical University, and completed Residency in Internal Medicine and a Clinical Research Fellowship in Addiction Medicine at Virginia Commonwealth University (VCU) Health System, and he is Board-certified in Internal Medicine through the American Board of Internal Medicine and certified in Addiction Medicine through the American Board of Preventive Medicine. Dr. Weaver is the Sub-Board Chair for Addiction Medicine on the American Board of Preventive Medicine, and also serves as the Chair of the Examination Committee for certification in Addiction Medicine. He has been a member of ASAM for over 20 years and currently serves as a member of the Publications Council and the Annual Conference Program Planning Committee. He is currently involved in patient care, medical education, and research. Dr. Weaver sees patients in the Innovations Addiction Treatment Clinic at the Texas Medical Center in Houston. He has extensive experience teaching about addiction to medical students, residents, and community professionals at all levels. He has been involved in multiple research projects, and currently is collaborating with other researchers in the CNRA on studies involving cocaine, methamphetamine, marijuana, and electronic cigarettes. Dr. Weaver has multiple publications in the field of addiction medicine, including the book "Addiction Treatment" published by Carlat Publishing in 2017.

    ACCME Accredited with Commendation

    CME/CE Credits

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this internet live course for a maximum of 1 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    NAADAC, the Association for Addiction Professionals

    This activity has been approved by the American Society of Addiction Medicine, as a NAADAC Approved Education Provider, for educational credits. NAADAC Provider #295, ASAM is responsible for all aspects of the programming.

    California Association for Drug/Alcohol Educators (CAADE)

    This educational program is approved by CAADE: #CP40 999 1222

    California Association of DUI Treatment Centers (CADTP)

    This educational program is approved by CADTP: #205

    Continuing Education Credits (CEUs)

    Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.

    Maintenance of Certification (MOC)

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1 LLSA credit towards ABPM MOC Part II requirements.

    ABA Maintenance of Certification (MOC)

    This activity contributes to the CME component of the American Board of Anesthesiology’s redesigned Maintenance of Certification in Anesthesiology TM (MOCA®) program, known as MOCA 2.0®.

    ABP Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn a maximum of 1 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.

    ABIM Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    ABAM Transitional Maintenance of Certification (Tmoc)

    Successful completion of this activity can be used to satisfy the American Board of Addiction Medicine (ABAM) for Tmoc as credits towards ABAM LLSA Part II requirements.

    American Board of Psychiatry and Neurology (ABPN)

    Successful completion of this CME activity can be used to satisfy the American Board of Psychiatry and Neurology’s (ABPN) CME requirement for Maintenance of Certification program.

    Program Planning Committee, CME Committee, Medical Education Council (MEC)

    In accordance with disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all CME activities. These policies include resolving all possible conflicts of interest for the Planning Committees, CME Committee, MEC, and Faculty. All activity Planning Committee members and Faculty have disclosed relevant financial relationship information. The ASAM CME Committee has reviewed these disclosures and determined that the relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity. 

    ASAM CME Committee Reviewer

    Ed Salsitz, MD, DFASAM - No Financial Disclosures

    Faculty & Planning Committee Disclosures

    Lewis S. Nelson, MD, FASAM (Chair) – No Relevant Financial Disclosures

    Kurt Kleinschmidt, MD, FASAM – No Relevant Financial Disclosures

    Gerald E. Marti, MD, PhD – No Relevant Financial Disclosures

    Darius Rastegar, MD, FASAM – No Relevant Financial Disclosures

    Dazhe Cao, MD – No Relevant Financial Disclosures

    George Kolodner, MD, DLFAPA, FASAM – Does Disclose: Kolmac Outpatient Recovery Centers, Self, Employment, Ownership Interest (includes stock, stock options, patent or other intellectual property) Clinical Condition: Substance Use Disorder

    Michael F. Weaver, MD, DFASAM – No Relevant Financial Disclosures


  • Treatment of Opioid Use Disorder: Waiver Qualifying - Troy, MI - Friday, October 9, 2020

    Product not yet rated Contains 4 Component(s), Includes Credits Includes a Live In-Person Event on 10/09/2020 at 8:00 AM (EDT)

    The ASAM Treatment of Opioid Use Disorder Course: Includes Waiver Qualifying Requirements covers treating opioid use disorder by using interactive, case-based learning to teach evidence-based practices.

    image

    Host: Michigan Opioid Collaborative

    Friday, October 9, 2020 | 8:00 am - 5:00 pm

    Michigan State University (MSU) Management Education Center (MEC)
    (Amphitheatre 101)
    811 W Square Lake Rd.
    Troy, MI 48098 

    Overview

    Welcome to the ASAM Treatment of Opioid Use Disorder Course. This course covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine. ASAM is an approved provider by CSAT/SAMHSA of DATA 2000 training. 

    Getting Started

    Please log in to begin. If you do not know your password, or you have forgotten it, select "Forgot Password" and you will be emailed a link to reset your password. Once you have completed the live course, return here to claim CME for the course. If you have any questions, please contact education@ASAM.org.

    Learning Objectives 

    Module 1 

    1. Assess patients for the full spectrum of harmful opioid use including misuse and use disorders
    2. Describe the current epidemiologic trends in opioid misuse including overdose and use disorders
    3. Recall opioid use neurobiology as it applies to the development of an opioid use disorder and relapse risk
    4. Summarize the laws regulating office-based opioid treatment including the Drug Addiction Treatment Act of 2000 and the Comprehensive Addiction and Recovery Act of 2016
    5. Summarize the clinical pharmacology, efficacy and safety of methadone, buprenorphine and naltrexone in treating opioid use disorders

    Module 2

    1. Identify and assess patients who are appropriate for treatment with medications for an opioid use disorder in an office-based setting
    2. Describe procedures for setting up office systems to support medication prescribing for opioid use disorders
    3. Describe procedures for initiating, stabilizing, maintaining, monitoring and modifying treatment of patients on buprenorphine or naltrexone

    Module 3

    1. Summarize the assessment and management of patients with psychiatric and medical co-morbidities associated with opioid use disorders
    2. Describe unique issues of treating adolescents, young adults, pregnant and postpartum patients maintained on medications for opioid use disorders
    3. Summarize acute and chronic pain management strategies for patients with an opioid use disorder

    Overall

    Apply for a waiver to prescribe buprenorphine to patients with opioid use disorder

    How to Claim CME

    1. Fill out the survey by clicking the “Fill out Survey” button in the box titled “Complete Live Portion Evaluation” at the end of the training.
      Pro tip: Be sure to scroll down on all Likert Scale questions. There are answers that expand past the size of the survey window.
    2. Submit the evaluation. (The next box should activate and the evaluation box should turn green with a white check mark)
    3. Click the button “Claim Medical Credits” in the box titled “CME Certificate”
    4. Choose the type of credit (Physician or Non-physician) and click submit.
    5. Click the button “View/Print Certificate” to save or print your certificate
      Pro tip: If you ever lose your certificate, you can come back to the e-Learning Center and view it on your Transcript (found on Dashboard)

    Accreditation & Disclosures

    Date of Release: July 2015
    Approved Through: July 2023

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this live activity for a maximum of 8 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been designated as an approved CME Activity by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of 8 AMA PRA Category 1 Credit(s)™ to the CME requirement for Part II: Lifelong Learning and Self-Assessment.

    Disclosures

    In accordance with the disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the CME Committee, Planning Committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All CME Committee, Planning Committee and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the content of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

    ASAM Treatment of Opioid Use Disorder Course Program Planning Committee

    NameNature of Relevant Financial Relationship
    Dan Alford, MD, MPH, DFASAM, ChairNone
    Edwin Salsitz, MD, DFASAM, Curriculum DirectorNone
    Alta DeRoo, MD, FASAM, FACOGNone
    Soraya Azari, MDNone
    Jill Mattingly, DHSc, MMSc, PA-CNone
    Debra Newman, PA-C, MPAS, MPHCommercial Interest: AbbVie
    What was received: Honoraria
    Role: Expert faculty for CME activities
    Commercial Interest: Gilead
    What was received: Honoraria
    Role: Expert faculty for CME activities
    Mary McMasters, MD, DFASAMNone
    Yngvild K. Olsen, MD, MPH, DFASAMNone
    Shawn Ryan, MD, MBA, FASAMCommercial Interest: Crosswave 
    What was received: Stock 
    Role: Advisor
    Commercial Interest: Dynamicare
    What was received: Stock
    Role: Advisor
    Kristin Smith, DNP, FNP-C, AAHIVSNone
    Tricia E. Wright, MD, MS, FACOG, DFASAMNone

    ASAM CME Committee

    NameNature of Relevant Financial Relationship
    Catherine Friedman, MD, FAPA, DFASAM, ChairNone
    Catharina Armstrong, MD, MPHNone
    Subhadeep Barman, MD, FASAM, FAPANone
    Benjamin Bearnot, MD, MPH, FASAMCommercial Interest: Johnson and Johnson
    What was received: Common stock
    Role: None
    Commercial Interest: Baxter International
    What was received: Common stock
    Role: None
    Commercial Interest: Takeda Pharmaceuticals
    What was received: Common stock
    Role: none
    R. Jeffrey Goldsmith, MD, DLFAPA, DFASAMCommercial Interest: Alkermes
    What was received: Travel expenses
    Role: Speaker
    Zwaantje H. Hamming, FNP-C, CARN-APNone
    Herbert L. Malinoff, MD, FACP, DFASAM None
    Noel Ilogu, MD, MRCP, DFASAMNone
    Edwin A. Salsitz, MD, DFASAMNone
     ASAM Staff and Consultants
    Arlene C. Deverman, MA, CAE, CFRENone
    Sandy MetcalfeNone
    Kate M. BrundageNone

    ASAM Medical Education Council

    NameNature of Relevant Financial Relationship
    Peter Selby, MBBS, CCFP, FCFP, MHSc, DFASAM, ChairCommercial Interest: Johnson & Johnson; Novartis; Pfizer Inc.
    What was received: Received free/discounted materials for research studies through an open tender process
    Role: Research Studies
    Commercial Interest: Pfizer Inc. Global Research Awards for Nicotine Dependence (GRAND).
    What was received: Grant funds
    Role: Principal investigator on research study
    Commercial Interest: Johnson & Johnson E-NRT Advisory Board
    What was received: Consulting Fees
    Role: Consulting on Johnson & Johnson E-NRT Advisory Board
    Daniel P. Alford, MD, MPH, DFASAMNone
    Michael Fingerhood, MD, FACP, FASAMNone
    Catherine R. Friedman, MD, FAPA, DFASAMNone
    Adam J. Gordon, MD, MPH, FACP, DFASAMNone
    Miriam S. Komaromy, MD, FACP, DFASAMNone
    Edwin A. Salsitz, MD, DFASAMNone
    Brian Hurley, MD, MBA, DFASAMNone
    Mark A. Weiner, MD, FASAMNone
     ASAM Staff and ConsultantsNone
    Penny S. Mills, MBANone
    Arlene C. Deverman, MA, CAE, CFRENone
    Marcia Jackson, PhDNone
    Dawn C. PiotrowskiNone
    Molly S. MazukNone
    Alexandra (Alli) KrouseNone
    Jennifer L. ButchartCommercial Interest: Merck
    What was received: Spouse received stocks
    Role: Stockholder


    Target Audience

    1. Physicians, Nurse Practitioners, Clinical Nurse Specialists, and Physician Assistants who wish to obtain a waiver to prescribe buprenorphine in office-based treatment of opioid use disorder.
    2. Clinicians and healthcare team members working with physicians who prescribe buprenorphine in office-based treatment of opioid use disorder.

    How to Apply for a Waiver

    Physicians

    SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.

    Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.

    If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.

    Other Approved Prescribers

    Apply

    NPs and PAs who have completed the 24 hours of required training may seek to obtain a DATA 2000 waiver for up to 30 patients by completing the Waiver Notification Form. Effective February 27, 2017, SAMHSA will only accept electronic submissions of the NOI.

    NPs and PAs may send copies of their training certificates to infobuprenorphine@samhsa.hhs.govor fax them to 301.576.5237. These waiver applications are forwarded to the Drug Enforcement Administration (DEA), which will assign the NP or PA a special identification number. DEA regulations require this number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with the NP’s or PA’s regular DEA registration number.

    SAMHSA shall review waiver applications within 45 days of receipt. If approved, NPs and PAs will receive a letter via email that confirms their waiver and includes their prescribing identification number. 

    Qualify

    To qualify for a waiver to treat patients with Opioid Use Disorder, NPs and PAs must:

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain
    • Complete no less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD
    • If required by state law, supervision or working in collaboration with a qualifying physician to prescribe medications for the treatment of OUD may be required.

    Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat OUD before you apply for the waiver.  Some states may have overriding state legislation that will prevent NPs from prescribing these medications even if Federal law allows it.

    Overview of Legislation

    Physicians

    The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies training is necessary for physicians to obtain a waiver to engage in office‐based treatment of opioid use disorders using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, who is one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses.

    Nurse Practitioners & Physician Assistants

    On July 22, 2016, President Obama signed the Comprehensive Addiction and Recovery Act (CARA) into law. CARA authorizes qualified NPs and PAs to become waivered to prescribe buprenorphine in office-based settings for patients with Opioid Use Disorder (OUD) for a five-year period expiring in October 2021.    

    To qualify, NPs and PAs must: 

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain  
    • Complete not less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD  
    • If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD

    HHS' announcement on November 16, 2016, enables NPs and PAs to immediately begin taking the 24 hours of required training. For the full HHS announcement, click here.

    NPs and PAs can begin the training immediately by taking the 8-hour buprenorphine course ASAM currently offers or that other stakeholders offer (see below for more information). The remaining 16 hours will have to be completed with one training provider. ASAM is developing multiple 16-hour training course options and formats, including collaborations with:

    The ASAM Treatment of Opioid Use Disorder Course has been made available in part by an unrestricted educational grant from Indivior, Inc.

  • Treatment of Opioid Use Disorder: Waiver Qualifying - Minneapolis, MN - Friday, October 2, 2020

    Product not yet rated Contains 7 Component(s), Includes Credits Includes a Live Web Event on 10/02/2020 at 9:00 AM (EDT)

    The ASAM Treatment of Opioid Use Disorder Course: Includes Waiver Qualifying Requirements covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine.

    image

    Host: University of Minnesota Medical School 
    Department of Obstetrics, Gynecology and Women's Health

    Date: Friday, October 2, 2020 | 8:00 am - 12:30 pm CT

    Live Virtual Course

    Online Portion Due: Thursday, October 1, 2020

    This course is offered in partnership with the American College of Obstetricians and Gynecologists (ACOG). The curriculum for this course has been specifically designed for women's health providers.

    Overview

    Welcome to The ASAM Treatment of Opioid Use Disorder Course online access. This course covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine. ASAM is an approved provider by CSAT/SAMHSA of DATA 2000 training. This is an 8-hour blended course combining 4 hours of online learning followed by 4 hours of live in person or via live webinar learning. The live in person or via live webinar portion of the course builds off content delivered in the online portion. Course faculty are expecting learners to complete the online portion before attending the live in person or via live webinar portion. You must complete both portions to receive credit for the course. 

    Getting Started

    To begin the online portion of the course, please log-in to your left and locate the box that says "View Course." If you do not know your password, or you have forgotten it, select "Forgot Password" and you will be emailed a link to reset your password.  If you have any questions, please contact education@ASAM.org.

    Learning Objectives

    1. Identify the importance of screening for substance use disorders
    2. Describe the mechanism of opioid withdrawal
    3. Discuss options to treat opioid withdrawal
    4. Explain the safety and efficacy of buprenorphine to treat opioid use disorder
    5. Explain the safety of medications in antepartum, postpartum, and breastfeeding period
    6. Describe how to start a patient (induction) on buprenorphine in an office-based setting
    7. Discuss successful non-pharmacological ways to treat Neonatal Abstinence Syndrome

    Overall Objective

    Apply for a waiver to prescribe buprenorphine to patients with opioid use disorder.

    Target Audience

    1. Physicians, Nurse Practitioners, Physician Assistants, Certified Nurse Midwives, Certified Registered Nurse Anesthetists, and Clinical Nurse Specialists who wish to obtain a waiver to prescribe buprenorphine in an office-based setting for opioid use disorder.
    2. Clinicians and healthcare team members working with physicians who prescribe buprenorphine in office-based treatment of opioid use disorder.
    ACCME Accredited with Commendation

    CME/CE Credits

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this live internet-based activity for a maximum of 4 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    The American Society of Addiction Medicine designates this enduring activity for a maximum of 4 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    NAADAC, the Association for Addiction Professionals

    This activity has been approved by the American Society of Addiction Medicine, as a NAADAC Approved Education Provider, for educational credits. NAADAC Provider #295, ASAM is responsible for all aspects of the programming.

    California Association for Drug/Alcohol Educators (CAADE)

    This educational program is approved by CAADE: #CP40 999 1222

    California Association of DUI Treatment Centers (CADTP)

    This educational program is approved by CADTP: #205

    Continuing Education Credits (CEUs)

    Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.

    Maintenance of Certification (MOC)

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 8 LLSA credit towards ABPM MOC Part II requirements.

    ABA Maintenance of Certification (MOC)

    This activity contributes to the CME component of the American Board of Anesthesiology’s redesigned Maintenance of Certification in Anesthesiology TM (MOCA®) program, known as MOCA 2.0®.

    ABP Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn a maximum of 8 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.

     ABIM Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    ABAM Transitional Maintenance of Certification (Tmoc)

    Successful completion of this activity can be used to satisfy the American Board of Addiction Medicine (ABAM) for Tmoc as credits towards ABAM LLSA Part II requirements.

    American Board of Psychiatry and Neurology (ABPN)

    Successful completion of this CME activity can be used to satisfy the American Board of Psychiatry and Neurology’s (ABPN) CME requirement for Maintenance of Certification program.

    Program Planning Committee, CME Committee, Medical Education Council (MEC), and Faculty Disclosure Information

    In accordance with disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all CME activities. These policies include resolving all possible conflicts of interest for the Planning Committees, CME Committee, MEC, and Faculty. All activity Planning Committee members and Faculty have disclosed relevant financial relationship information. The ASAM CME Committee has reviewed these disclosures and determined that the relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

    ASAM Treatment of Opioid Use Disorder Course Program Planning Committee

    NameNature of Relevant Financial Relationship
    Dan Alford, MD, MPH, DFASAM, ChairNone
    Edwin Salsitz, MD, DFASAM, Curriculum DirectorNone
    Alta DeRoo, MD, FASAM, FACOGNone
    Soraya Azari, MDNone
    Jill Mattingly, DHSc, MMSc, PA-CNone
    Debra Newman, PA-C, MPAS, MPHCommercial Interest: AbbVie
    What was received: Honoraria
    Role: Expert faculty for CME activities
    Commercial Interest: Gilead
    What was received: Honoraria
    Role: Expert faculty for CME activities
    Mary McMasters, MD, DFASAMNone
    Yngvild K. Olsen, MD, MPH, DFASAMNone
    Shawn Ryan, MD, MBA, FASAMCommercial Interest: Crosswave 
    What was received: Stock 
    Role: Advisor
    Commercial Interest: Dynamicare
    What was received: Stock
    Role: Advisor
    Kristin Smith, DNP, FNP-C, AAHIVSNone
    Tricia E. Wright, MD, MS, FACOG, DFASAMNone

    ASAM CME Committee

    NameNature of Relevant Financial Relationship
    Catherine Friedman, MD, FAPA, DFASAM, ChairNone
    Catharina Armstrong, MD, MPHNone
    Subhadeep Barman, MD, FASAM, FAPANone
    Benjamin Bearnot, MD, MPH, FASAMCommercial Interest: Johnson and Johnson
    What was received: Common stock
    Role: None
    Commercial Interest: Baxter International
    What was received: Common stock
    Role: None
    Commercial Interest: Takeda Pharmaceuticals
    What was received: Common stock
    Role: none
    R. Jeffrey Goldsmith, MD, DLFAPA, DFASAMCommercial Interest: Alkermes
    What was received: Travel expenses
    Role: Speaker
    Zwaantje H. Hamming, FNP-C, CARN-APNone
    Herbert L. Malinoff, MD, FACP, DFASAM None
    Noel Ilogu, MD, MRCP, DFASAMNone
    Edwin A. Salsitz, MD, DFASAMNone
     ASAM Staff and Consultants
    Arlene C. Deverman, MA, CAE, CFRENone
    Sandy MetcalfeNone
    Kate M. BrundageNone

    ASAM Medical Education Council

    NameNature of Relevant Financial Relationship
    Peter Selby, MBBS, CCFP, FCFP, MHSc, DFASAM, ChairCommercial Interest: Johnson & Johnson; Novartis; Pfizer Inc.
    What was received: Received free/discounted materials for research studies through an open tender process
    Role: Research Studies
    Commercial Interest: Pfizer Inc. Global Research Awards for Nicotine Dependence (GRAND).
    What was received: Grant funds
    Role: Principal investigator on research study
    Commercial Interest: Johnson & Johnson E-NRT Advisory Board
    What was received: Consulting Fees
    Role: Consulting on Johnson & Johnson E-NRT Advisory Board
    Daniel P. Alford, MD, MPH, DFASAMNone
    Michael Fingerhood, MD, FACP, FASAMNone
    Catherine R. Friedman, MD, FAPA, DFASAMNone
    Adam J. Gordon, MD, MPH, FACP, DFASAMNone
    Miriam S. Komaromy, MD, FACP, DFASAMNone
    Edwin A. Salsitz, MD, DFASAMNone
    Brian Hurley, MD, MBA, DFASAMNone
    Mark A. Weiner, MD, FASAMNone
     ASAM Staff and ConsultantsNone
    Penny S. Mills, MBANone
    Arlene C. Deverman, MA, CAE, CFRENone
    Marcia Jackson, PhDNone
    Dawn C. PiotrowskiNone
    Molly S. MazukNone
    Alexandra (Alli) KrouseNone
    Jennifer L. ButchartCommercial Interest: Merck
    What was received: Spouse received stocks
    Role: Stockholder


    How to Apply for a Waiver

    Physicians

    SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.

    Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.

    If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.

    Other Approved Prescribers

    Apply

    NPs and PAs who have completed the 24 hours of required training may seek to obtain a DATA 2000 waiver for up to 30 patients by completing the Waiver Notification Form. Effective February 27, 2017, SAMHSA will only accept electronic submissions of the NOI.

    NPs and PAs may send copies of their training certificates to csatbupinfo@dsgonline.com. These waiver applications are forwarded to the Drug Enforcement Administration (DEA), which will assign the NP or PA a special identification number. DEA regulations require this number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with the NP’s or PA’s regular DEA registration number.

    SAMHSA shall review waiver applications within 45 days of receipt. If approved, NPs and PAs will receive a letter via email that confirms their waiver and includes their prescribing identification number. 

    Qualify

    To qualify for a waiver to treat patients with Opioid Use Disorder, NPs and PAs must:

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain
    • Complete no less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD
    • If required by state law, supervision or working in collaboration with a qualifying physician to prescribe medications for the treatment of OUD may be required.

    Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat OUD before you apply for the waiver.  Some states may have overriding state legislation that will prevent NPs from prescribing these medications even if Federal law allows it.

    Overview of Legislation

    Physicians

    The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies training is necessary for physicians to obtain a waiver to engage in office‐based treatment of opioid use disorders using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, who is one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses.

    Nurse Practitioners & Physician Assistants

    On July 22, 2016, President Obama signed the Comprehensive Addiction and Recovery Act (CARA) into law. CARA authorizes qualified NPs and PAs to become waivered to prescribe buprenorphine in office-based settings for patients with Opioid Use Disorder (OUD) for a five-year period expiring in October 2021.    

    To qualify, NPs and PAs must: 

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain  
    • Complete not less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD  
    • If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD

    HHS' announcement on November 16, 2016, enables NPs and PAs to immediately begin taking the 24 hours of required training. For the full HHS announcement, click here.

    NPs and PAs can begin the training immediately by taking the 8-hour buprenorphine course ASAM currently offers or that other stakeholders offer (see below for more information). The remaining 16 hours will have to be completed with one training provider. ASAM is developing multiple 16-hour training course options and formats, including collaborations with:

  • Treatment of Opioid Use Disorder: Waiver Qualifying - Philadelphia, PA - Wednesday, September 30, 2020

    Product not yet rated Contains 7 Component(s), Includes Credits Includes a Live Web Event on 09/30/2020 at 8:00 AM (EDT)

    The ASAM Treatment of Opioid Use Disorder Course: Includes Waiver Qualifying Requirements covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine.

    image

    Host: Pennsylvania Perinatal Quality Collaborative (PA PQC)
    and Jewish Healthcare Foundation

    Date: Wednesday, September 30, 2020 | 8:00 am - 12:30 pm ET

    Live Virtual Course

    Online Portion Due: Tuesday, September 29, 2020

    This course is offered in partnership with the American College of Obstetricians and Gynecologists (ACOG). The curriculum for this course has been specifically designed for women's health providers.

    Overview

    Welcome to The ASAM Treatment of Opioid Use Disorder Course online access. This course covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine. ASAM is an approved provider by CSAT/SAMHSA of DATA 2000 training. This is an 8-hour blended course combining 4 hours of online learning followed by 4 hours of live in person or via live webinar learning. The live in person or via live webinar portion of the course builds off content delivered in the online portion. Course faculty are expecting learners to complete the online portion before attending the live in person or via live webinar portion. You must complete both portions to receive credit for the course. 

    Getting Started

    To begin the online portion of the course, please log-in to your left and locate the box that says "View Course." If you do not know your password, or you have forgotten it, select "Forgot Password" and you will be emailed a link to reset your password.  If you have any questions, please contact education@ASAM.org.

    Learning Objectives

    1. Identify the importance of screening for substance use disorders
    2. Describe the mechanism of opioid withdrawal
    3. Discuss options to treat opioid withdrawal
    4. Explain the safety and efficacy of buprenorphine to treat opioid use disorder
    5. Explain the safety of medications in antepartum, postpartum, and breastfeeding period
    6. Describe how to start a patient (induction) on buprenorphine in an office-based setting
    7. Discuss successful non-pharmacological ways to treat Neonatal Abstinence Syndrome

    Overall Objective

    Apply for a waiver to prescribe buprenorphine to patients with opioid use disorder.

    Target Audience

    1. Physicians, Nurse Practitioners, Physician Assistants, Certified Nurse Midwives, Certified Registered Nurse Anesthetists, and Clinical Nurse Specialists who wish to obtain a waiver to prescribe buprenorphine in an office-based setting for opioid use disorder.
    2. Clinicians and healthcare team members working with physicians who prescribe buprenorphine in office-based treatment of opioid use disorder.
    ACCME Accredited with Commendation

    CME/CE Credits

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this live internet-based activity for a maximum of 4 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    The American Society of Addiction Medicine designates this enduring activity for a maximum of 4 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    NAADAC, the Association for Addiction Professionals

    This activity has been approved by the American Society of Addiction Medicine, as a NAADAC Approved Education Provider, for educational credits. NAADAC Provider #295, ASAM is responsible for all aspects of the programming.

    California Association for Drug/Alcohol Educators (CAADE)

    This educational program is approved by CAADE: #CP40 999 1222

    California Association of DUI Treatment Centers (CADTP)

    This educational program is approved by CADTP: #205

    Continuing Education Credits (CEUs)

    Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.

    Maintenance of Certification (MOC)

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 8 LLSA credit towards ABPM MOC Part II requirements.

    ABA Maintenance of Certification (MOC)

    This activity contributes to the CME component of the American Board of Anesthesiology’s redesigned Maintenance of Certification in Anesthesiology TM (MOCA®) program, known as MOCA 2.0®.

    ABP Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn a maximum of 8 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.

     ABIM Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    ABAM Transitional Maintenance of Certification (Tmoc)

    Successful completion of this activity can be used to satisfy the American Board of Addiction Medicine (ABAM) for Tmoc as credits towards ABAM LLSA Part II requirements.

    American Board of Psychiatry and Neurology (ABPN)

    Successful completion of this CME activity can be used to satisfy the American Board of Psychiatry and Neurology’s (ABPN) CME requirement for Maintenance of Certification program.

    Program Planning Committee, CME Committee, Medical Education Council (MEC), and Faculty Disclosure Information

    In accordance with disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all CME activities. These policies include resolving all possible conflicts of interest for the Planning Committees, CME Committee, MEC, and Faculty. All activity Planning Committee members and Faculty have disclosed relevant financial relationship information. The ASAM CME Committee has reviewed these disclosures and determined that the relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

    ASAM Treatment of Opioid Use Disorder Course Program Planning Committee

    NameNature of Relevant Financial Relationship
    Dan Alford, MD, MPH, DFASAM, ChairNone
    Edwin Salsitz, MD, DFASAM, Curriculum DirectorNone
    Alta DeRoo, MD, FASAM, FACOGNone
    Soraya Azari, MDNone
    Jill Mattingly, DHSc, MMSc, PA-CNone
    Debra Newman, PA-C, MPAS, MPHCommercial Interest: AbbVie
    What was received: Honoraria
    Role: Expert faculty for CME activities
    Commercial Interest: Gilead
    What was received: Honoraria
    Role: Expert faculty for CME activities
    Mary McMasters, MD, DFASAMNone
    Yngvild K. Olsen, MD, MPH, DFASAMNone
    Shawn Ryan, MD, MBA, FASAMCommercial Interest: Crosswave 
    What was received: Stock 
    Role: Advisor
    Commercial Interest: Dynamicare
    What was received: Stock
    Role: Advisor
    Kristin Smith, DNP, FNP-C, AAHIVSNone
    Tricia E. Wright, MD, MS, FACOG, DFASAMNone

    ASAM CME Committee

    NameNature of Relevant Financial Relationship
    Catherine Friedman, MD, FAPA, DFASAM, ChairNone
    Catharina Armstrong, MD, MPHNone
    Subhadeep Barman, MD, FASAM, FAPANone
    Benjamin Bearnot, MD, MPH, FASAMCommercial Interest: Johnson and Johnson
    What was received: Common stock
    Role: None
    Commercial Interest: Baxter International
    What was received: Common stock
    Role: None
    Commercial Interest: Takeda Pharmaceuticals
    What was received: Common stock
    Role: none
    R. Jeffrey Goldsmith, MD, DLFAPA, DFASAMCommercial Interest: Alkermes
    What was received: Travel expenses
    Role: Speaker
    Zwaantje H. Hamming, FNP-C, CARN-APNone
    Herbert L. Malinoff, MD, FACP, DFASAM None
    Noel Ilogu, MD, MRCP, DFASAMNone
    Edwin A. Salsitz, MD, DFASAMNone
     ASAM Staff and Consultants
    Arlene C. Deverman, MA, CAE, CFRENone
    Sandy MetcalfeNone
    Kate M. BrundageNone

    ASAM Medical Education Council

    NameNature of Relevant Financial Relationship
    Peter Selby, MBBS, CCFP, FCFP, MHSc, DFASAM, ChairCommercial Interest: Johnson & Johnson; Novartis; Pfizer Inc.
    What was received: Received free/discounted materials for research studies through an open tender process
    Role: Research Studies
    Commercial Interest: Pfizer Inc. Global Research Awards for Nicotine Dependence (GRAND).
    What was received: Grant funds
    Role: Principal investigator on research study
    Commercial Interest: Johnson & Johnson E-NRT Advisory Board
    What was received: Consulting Fees
    Role: Consulting on Johnson & Johnson E-NRT Advisory Board
    Daniel P. Alford, MD, MPH, DFASAMNone
    Michael Fingerhood, MD, FACP, FASAMNone
    Catherine R. Friedman, MD, FAPA, DFASAMNone
    Adam J. Gordon, MD, MPH, FACP, DFASAMNone
    Miriam S. Komaromy, MD, FACP, DFASAMNone
    Edwin A. Salsitz, MD, DFASAMNone
    Brian Hurley, MD, MBA, DFASAMNone
    Mark A. Weiner, MD, FASAMNone
     ASAM Staff and ConsultantsNone
    Penny S. Mills, MBANone
    Arlene C. Deverman, MA, CAE, CFRENone
    Marcia Jackson, PhDNone
    Dawn C. PiotrowskiNone
    Molly S. MazukNone
    Alexandra (Alli) KrouseNone
    Jennifer L. ButchartCommercial Interest: Merck
    What was received: Spouse received stocks
    Role: Stockholder


    How to Apply for a Waiver

    Physicians

    SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.

    Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.

    If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.

    Other Approved Prescribers

    Apply

    NPs and PAs who have completed the 24 hours of required training may seek to obtain a DATA 2000 waiver for up to 30 patients by completing the Waiver Notification Form. Effective February 27, 2017, SAMHSA will only accept electronic submissions of the NOI.

    NPs and PAs may send copies of their training certificates to csatbupinfo@dsgonline.com. These waiver applications are forwarded to the Drug Enforcement Administration (DEA), which will assign the NP or PA a special identification number. DEA regulations require this number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with the NP’s or PA’s regular DEA registration number.

    SAMHSA shall review waiver applications within 45 days of receipt. If approved, NPs and PAs will receive a letter via email that confirms their waiver and includes their prescribing identification number. 

    Qualify

    To qualify for a waiver to treat patients with Opioid Use Disorder, NPs and PAs must:

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain
    • Complete no less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD
    • If required by state law, supervision or working in collaboration with a qualifying physician to prescribe medications for the treatment of OUD may be required.

    Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat OUD before you apply for the waiver.  Some states may have overriding state legislation that will prevent NPs from prescribing these medications even if Federal law allows it.

    Overview of Legislation

    Physicians

    The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies training is necessary for physicians to obtain a waiver to engage in office‐based treatment of opioid use disorders using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, who is one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses.

    Nurse Practitioners & Physician Assistants

    On July 22, 2016, President Obama signed the Comprehensive Addiction and Recovery Act (CARA) into law. CARA authorizes qualified NPs and PAs to become waivered to prescribe buprenorphine in office-based settings for patients with Opioid Use Disorder (OUD) for a five-year period expiring in October 2021.    

    To qualify, NPs and PAs must: 

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain  
    • Complete not less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD  
    • If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD

    HHS' announcement on November 16, 2016, enables NPs and PAs to immediately begin taking the 24 hours of required training. For the full HHS announcement, click here.

    NPs and PAs can begin the training immediately by taking the 8-hour buprenorphine course ASAM currently offers or that other stakeholders offer (see below for more information). The remaining 16 hours will have to be completed with one training provider. ASAM is developing multiple 16-hour training course options and formats, including collaborations with:

  • Treatment of Opioid Use Disorder: Waiver Qualifying - SLUSSM - Friday, September 25, 2020

    Product not yet rated Contains 7 Component(s), Includes Credits Includes a Live Web Event on 09/25/2020 at 9:00 AM (EDT)

    The ASAM Treatment of Opioid Use Disorder Course covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine.

    image

    Host: St. Louis University School of Medicine and SSM Health

    Friday, September 25, 2020 | 8:00 am CT - 12:30 pm CT

    Live Virtual Course

    Online Portion Due: Thursday, September 24, 2020

    This course is offered in partnership with the American College of Obstetricians and Gynecologists (ACOG). The curriculum for this course has been specifically designed for women's health providers.

    Overview

    Welcome to The ASAM Treatment of Opioid Use Disorder Course online access. This course covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine. ASAM is an approved provider by CSAT/SAMHSA of DATA 2000 training. This is an 8-hour blended course combining 4 hours of online learning followed by 4 hours of live webinar learning. The live webinar portion of the course builds off content delivered in the online portion. Course faculty are expecting learners to complete the online portion before attending the live webinar portion. You must complete both portions to receive credit for the course. 

    Getting Started

    To begin the online portion of the course, please log-in to your left and locate the box that says "View Course." If you do not know your password, or you have forgotten it, select "Forgot Password" and you will be emailed a link to reset your password. If you have any questions, please contact education@ASAM.org.

    Learning Objectives

    1. Identify the importance of screening for substance use disorders
    2. Describe the mechanism of opioid withdrawal
    3. Discuss options to treat opioid withdrawal
    4. Explain the safety and efficacy of buprenorphine to treat opioid use disorder
    5. Explain the safety of medications in antepartum, postpartum, and breastfeeding period
    6. Describe how to start a patient (induction) on buprenorphine in an office-based setting
    7. Discuss successful non-pharmacological ways to treat Neonatal Abstinence Syndrome

    Overall Objective

    Apply for a waiver to prescribe buprenorphine to patients with opioid use disorder.

    Target Audience

    1. Physicians, Nurse Practitioners, Physician Assistants, Certified Nurse Midwives, Certified Registered Nurse Anesthetists, and Clinical Nurse Specialists who wish to obtain a waiver to prescribe buprenorphine in an office-based setting for opioid use disorder.
    2. Clinicians and healthcare team members working with physicians who prescribe buprenorphine in office-based treatment of opioid use disorder.
    ACCME Accredited with Commendation

    CME/CE Credits

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this live internet-based activity for a maximum of 4 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    The American Society of Addiction Medicine designates this enduring activity for a maximum of 4 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    NAADAC, the Association for Addiction Professionals

    This activity has been approved by the American Society of Addiction Medicine, as a NAADAC Approved Education Provider, for educational credits. NAADAC Provider #295, ASAM is responsible for all aspects of the programming.

    California Association for Drug/Alcohol Educators (CAADE)

    This educational program is approved by CAADE: #CP40 999 1222

    California Association of DUI Treatment Centers (CADTP)

    This educational program is approved by CADTP: #205

    Continuing Education Credits (CEUs)

    Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.

    Maintenance of Certification (MOC)

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 8 LLSA credit towards ABPM MOC Part II requirements.

    ABA Maintenance of Certification (MOC)

    This activity contributes to the CME component of the American Board of Anesthesiology’s redesigned Maintenance of Certification in Anesthesiology TM (MOCA®) program, known as MOCA 2.0®.

    ABP Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn a maximum of 8 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.

     ABIM Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    ABAM Transitional Maintenance of Certification (Tmoc)

    Successful completion of this activity can be used to satisfy the American Board of Addiction Medicine (ABAM) for Tmoc as credits towards ABAM LLSA Part II requirements.

    American Board of Psychiatry and Neurology (ABPN)

    Successful completion of this CME activity can be used to satisfy the American Board of Psychiatry and Neurology’s (ABPN) CME requirement for Maintenance of Certification program.

    Program Planning Committee, CME Committee, Medical Education Council (MEC), and Faculty Disclosure Information

    In accordance with disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all CME activities. These policies include resolving all possible conflicts of interest for the Planning Committees, CME Committee, MEC, and Faculty. All activity Planning Committee members and Faculty have disclosed relevant financial relationship information. The ASAM CME Committee has reviewed these disclosures and determined that the relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

    ASAM Treatment of Opioid Use Disorder Course Program Planning Committee

    NameNature of Relevant Financial Relationship
    Dan Alford, MD, MPH, DFASAM, ChairNone
    Edwin Salsitz, MD, DFASAM, Curriculum DirectorNone
    Alta DeRoo, MD, FASAM, FACOGNone
    Soraya Azari, MDNone
    Jill Mattingly, DHSc, MMSc, PA-CNone
    Debra Newman, PA-C, MPAS, MPHCommercial Interest: AbbVie
    What was received: Honoraria
    Role: Expert faculty for CME activities
    Commercial Interest: Gilead
    What was received: Honoraria
    Role: Expert faculty for CME activities
    Mary McMasters, MD, DFASAMNone
    Yngvild K. Olsen, MD, MPH, DFASAMNone
    Shawn Ryan, MD, MBA, FASAMCommercial Interest: Crosswave 
    What was received: Stock 
    Role: Advisor
    Commercial Interest: Dynamicare
    What was received: Stock
    Role: Advisor
    Kristin Smith, DNP, FNP-C, AAHIVSNone
    Tricia E. Wright, MD, MS, FACOG, DFASAMNone

    ASAM CME Committee

    NameNature of Relevant Financial Relationship
    Catherine Friedman, MD, FAPA, DFASAM, ChairNone
    Catharina Armstrong, MD, MPHNone
    Subhadeep Barman, MD, FASAM, FAPANone
    Benjamin Bearnot, MD, MPH, FASAMCommercial Interest: Johnson and Johnson
    What was received: Common stock
    Role: None
    Commercial Interest: Baxter International
    What was received: Common stock
    Role: None
    Commercial Interest: Takeda Pharmaceuticals
    What was received: Common stock
    Role: none
    R. Jeffrey Goldsmith, MD, DLFAPA, DFASAMCommercial Interest: Alkermes
    What was received: Travel expenses
    Role: Speaker
    Zwaantje H. Hamming, FNP-C, CARN-APNone
    Herbert L. Malinoff, MD, FACP, DFASAM None
    Noel Ilogu, MD, MRCP, DFASAMNone
    Edwin A. Salsitz, MD, DFASAMNone
     ASAM Staff and Consultants
    Arlene C. Deverman, MA, CAE, CFRENone
    Sandy MetcalfeNone
    Kate M. BrundageNone

    ASAM Medical Education Council

    NameNature of Relevant Financial Relationship
    Peter Selby, MBBS, CCFP, FCFP, MHSc, DFASAM, ChairCommercial Interest: Johnson & Johnson; Novartis; Pfizer Inc.
    What was received: Received free/discounted materials for research studies through an open tender process
    Role: Research Studies
    Commercial Interest: Pfizer Inc. Global Research Awards for Nicotine Dependence (GRAND).
    What was received: Grant funds
    Role: Principal investigator on research study
    Commercial Interest: Johnson & Johnson E-NRT Advisory Board
    What was received: Consulting Fees
    Role: Consulting on Johnson & Johnson E-NRT Advisory Board
    Daniel P. Alford, MD, MPH, DFASAMNone
    Michael Fingerhood, MD, FACP, FASAMNone
    Catherine R. Friedman, MD, FAPA, DFASAMNone
    Adam J. Gordon, MD, MPH, FACP, DFASAMNone
    Miriam S. Komaromy, MD, FACP, DFASAMNone
    Edwin A. Salsitz, MD, DFASAMNone
    Brian Hurley, MD, MBA, DFASAMNone
    Mark A. Weiner, MD, FASAMNone
     ASAM Staff and ConsultantsNone
    Penny S. Mills, MBANone
    Arlene C. Deverman, MA, CAE, CFRENone
    Marcia Jackson, PhDNone
    Dawn C. PiotrowskiNone
    Molly S. MazukNone
    Alexandra (Alli) KrouseNone
    Jennifer L. ButchartCommercial Interest: Merck
    What was received: Spouse received stocks
    Role: Stockholder


    How to Apply for a Waiver

    Physicians

    SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.

    Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.

    If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.

    Other Approved Prescribers

    Apply

    NPs and PAs who have completed the 24 hours of required training may seek to obtain a DATA 2000 waiver for up to 30 patients by completing the Waiver Notification Form. Effective February 27, 2017, SAMHSA will only accept electronic submissions of the NOI.

    NPs and PAs may send copies of their training certificates to csatbupinfo@dsgonline.com. These waiver applications are forwarded to the Drug Enforcement Administration (DEA), which will assign the NP or PA a special identification number. DEA regulations require this number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with the NP’s or PA’s regular DEA registration number.

    SAMHSA shall review waiver applications within 45 days of receipt. If approved, NPs and PAs will receive a letter via email that confirms their waiver and includes their prescribing identification number. 

    Qualify

    To qualify for a waiver to treat patients with Opioid Use Disorder, NPs and PAs must:

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain
    • Complete no less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD
    • If required by state law, supervision or working in collaboration with a qualifying physician to prescribe medications for the treatment of OUD may be required.

    Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat OUD before you apply for the waiver.  Some states may have overriding state legislation that will prevent NPs from prescribing these medications even if Federal law allows it.

    Overview of Legislation

    Physicians

    The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies training is necessary for physicians to obtain a waiver to engage in office‐based treatment of opioid use disorders using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, who is one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses.

    Nurse Practitioners & Physician Assistants

    On July 22, 2016, President Obama signed the Comprehensive Addiction and Recovery Act (CARA) into law. CARA authorizes qualified NPs and PAs to become waivered to prescribe buprenorphine in office-based settings for patients with Opioid Use Disorder (OUD) for a five-year period expiring in October 2021.    

    To qualify, NPs and PAs must: 

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain  
    • Complete not less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD  
    • If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD

    HHS' announcement on November 16, 2016, enables NPs and PAs to immediately begin taking the 24 hours of required training. For the full HHS announcement, click here.

    NPs and PAs can begin the training immediately by taking the 8-hour buprenorphine course ASAM currently offers or that other stakeholders offer (see below for more information). The remaining 16 hours will have to be completed with one training provider. ASAM is developing multiple 16-hour training course options and formats, including collaborations with:

  • Treatment of Opioid Use Disorder: Waiver Qualifying - Marquette, MI - Friday, September 25, 2020

    Product not yet rated Contains 4 Component(s), Includes Credits Includes a Live In-Person Event on 09/25/2020 at 8:00 AM (EDT)

    The ASAM Treatment of Opioid Use Disorder Course: Includes Waiver Qualifying Requirements covers treating opioid use disorder by using interactive, case-based learning to teach evidence-based practices.

    image

    Host: Michigan Opioid Collaborative

    Friday, September 25, 2020 |8:00 am - 5:00 pm

    Upper Peninsula Health Plan
    853 West Washington Street
    Marquette, Michigan 49855

    Overview

    Welcome to the ASAM Treatment of Opioid Use Disorder Course. This course covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine. ASAM is an approved provider by CSAT/SAMHSA of DATA 2000 training. 

    Getting Started

    Please LOG IN to begin. If you do not know your password, or you have forgotten it, select "Forgot Password" and you will be emailed a link to reset your password. Once you have completed the live course, return here to claim CME for the course. If you have any questions, please contact education@ASAM.org.

    Learning Objectives 

    Module 1 

    1. Assess patients for the full spectrum of harmful opioid use including misuse and use disorders
    2. Describe the current epidemiologic trends in opioid misuse including overdose and use disorders
    3. Recall opioid use neurobiology as it applies to the development of an opioid use disorder and relapse risk
    4. Summarize the laws regulating office-based opioid treatment including the Drug Addiction Treatment Act of 2000 and the Comprehensive Addiction and Recovery Act of 2016
    5. Summarize the clinical pharmacology, efficacy and safety of methadone, buprenorphine and naltrexone in treating opioid use disorders

    Module 2

    1. Identify and assess patients who are appropriate for treatment with medications for an opioid use disorder in an office-based setting
    2. Describe procedures for setting up office systems to support medication prescribing for opioid use disorders
    3. Describe procedures for initiating, stabilizing, maintaining, monitoring and modifying treatment of patients on buprenorphine or naltrexone

    Module 3

    1. Summarize the assessment and management of patients with psychiatric and medical co-morbidities associated with opioid use disorders
    2. Describe unique issues of treating adolescents, young adults, pregnant and postpartum patients maintained on medications for opioid use disorders
    3. Summarize acute and chronic pain management strategies for patients with an opioid use disorder

    Overall

    Apply for a waiver to prescribe buprenorphine to patients with opioid use disorder

    Please park in the UPHP parking lot (off of main entrance). Additional parking along the front of Staybridge Suites (avoid parking at mBank). Upon arrival, please register at reception and a UPHG representative will meet you and take you to the conference room located on the second floor.

    Accreditation & Disclosures

    Date of Release: July 2015
    Approved Through: July 2023

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this live activity for a maximum of 8 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been designated as an approved CME Activity by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of 8 AMA PRA Category 1 Credit(s)™ to the CME requirement for Part II: Lifelong Learning and Self-Assessment.

    Disclosures

    In accordance with the disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the CME Committee, Planning Committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All CME Committee, Planning Committee and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the content of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

    ASAM Treatment of Opioid Use Disorder Course Program Planning Committee

    NameNature of Relevant Financial Relationship
    Dan Alford, MD, MPH, DFASAM, ChairNone
    Edwin Salsitz, MD, DFASAM, Curriculum DirectorNone
    Alta DeRoo, MD, FASAM, FACOGNone
    Soraya Azari, MDNone
    Jill Mattingly, DHSc, MMSc, PA-CNone
    Debra Newman, PA-C, MPAS, MPHCommercial Interest: AbbVie
    What was received: Honoraria
    Role: Expert faculty for CME activities
    Commercial Interest: Gilead
    What was received: Honoraria
    Role: Expert faculty for CME activities
    Mary McMasters, MD, DFASAMNone
    Yngvild K. Olsen, MD, MPH, DFASAMNone
    Shawn Ryan, MD, MBA, FASAMCommercial Interest: Crosswave 
    What was received: Stock 
    Role: Advisor
    Commercial Interest: Dynamicare
    What was received: Stock
    Role: Advisor
    Kristin Smith, DNP, FNP-C, AAHIVSNone
    Tricia E. Wright, MD, MS, FACOG, DFASAMNone

    ASAM CME Committee

    NameNature of Relevant Financial Relationship
    Catherine Friedman, MD, FAPA, DFASAM, ChairNone
    Catharina Armstrong, MD, MPHNone
    Subhadeep Barman, MD, FASAM, FAPANone
    Benjamin Bearnot, MD, MPH, FASAMCommercial Interest: Johnson and Johnson
    What was received: Common stock
    Role: None
    Commercial Interest: Baxter International
    What was received: Common stock
    Role: None
    Commercial Interest: Takeda Pharmaceuticals
    What was received: Common stock
    Role: none
    R. Jeffrey Goldsmith, MD, DLFAPA, DFASAMCommercial Interest: Alkermes
    What was received: Travel expenses
    Role: Speaker
    Zwaantje H. Hamming, FNP-C, CARN-APNone
    Herbert L. Malinoff, MD, FACP, DFASAM None
    Noel Ilogu, MD, MRCP, DFASAMNone
    Edwin A. Salsitz, MD, DFASAMNone
     ASAM Staff and Consultants
    Arlene C. Deverman, MA, CAE, CFRENone
    Marcia Jackson, PhDNone
    Kate M. BrundageNone

    ASAM Medical Education Council

    NameNature of Relevant Financial Relationship
    Peter Selby, MBBS, CCFP, FCFP, MHSc, DFASAM, ChairCommercial Interest: Johnson & Johnson; Novartis; Pfizer Inc.
    What was received: Received free/discounted materials for research studies through an open tender process
    Role: Research Studies
    Commercial Interest: Pfizer Inc. Global Research Awards for Nicotine Dependence (GRAND).
    What was received: Grant funds
    Role: Principal investigator on research study
    Commercial Interest: Johnson & Johnson E-NRT Advisory Board
    What was received: Consulting Fees
    Role: Consulting on Johnson & Johnson E-NRT Advisory Board
    Daniel P. Alford, MD, MPH, DFASAMNone
    Michael Fingerhood, MD, FACP, FASAMNone
    Catherine R. Friedman, MD, FAPA, DFASAMNone
    Adam J. Gordon, MD, MPH, FACP, DFASAMNone
    Miriam S. Komaromy, MD, FACP, DFASAMNone
    Edwin A. Salsitz, MD, DFASAMNone
    Brian Hurley, MD, MBA, DFASAMNone
    Mark A. Weiner, MD, FASAMNone
     ASAM Staff and ConsultantsNone
    Penny S. Mills, MBANone
    Arlene C. Deverman, MA, CAE, CFRENone
    Marcia Jackson, PhDNone
    Dawn C. PiotrowskiNone
    Molly S. MazukNone
    Alexandra (Alli) KrouseNone
    Jennifer L. ButchartCommercial Interest: Merck
    What was received: Spouse received stocks
    Role: Stockholder


    Target Audience

    1. Physicians, Nurse Practitioners, Clinical Nurse Specialists, and Physician Assistants who wish to obtain a waiver to prescribe buprenorphine in office-based treatment of opioid use disorder.
    2. Clinicians and healthcare team members working with physicians who prescribe buprenorphine in office-based treatment of opioid use disorder.

    How to Claim CME

    1. Fill out the survey by clicking the “Fill out Survey” button in the box titled “Complete Live Portion Evaluation” at the end of the training.
      Pro tip: Be sure to scroll down on all Likert Scale questions. There are answers that expand past the size of the survey window.
    2. Submit the evaluation. (The next box should activate and the evaluation box should turn green with a white check mark)
    3. Click the button “Claim Medical Credits” in the box titled “CME Certificate”
    4. Choose the type of credit (Physician or Non-physician) and click submit.
    5. Click the button “View/Print Certificate” to save or print your certificate
      Pro tip: If you ever lose your certificate, you can come back to the e-Learning Center and view it on your Transcript (found on Dashboard)

    How to Apply for a Waiver

    Physicians

    SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.

    Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.

    If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.

    Other Approved Prescribers

    Apply

    NPs and PAs who have completed the 24 hours of required training may seek to obtain a DATA 2000 waiver for up to 30 patients by completing the Waiver Notification Form. Effective February 27, 2017, SAMHSA will only accept electronic submissions of the NOI.

    NPs and PAs may send copies of their training certificates to infobuprenorphine@samhsa.hhs.govor fax them to 301.576.5237. These waiver applications are forwarded to the Drug Enforcement Administration (DEA), which will assign the NP or PA a special identification number. DEA regulations require this number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with the NP’s or PA’s regular DEA registration number.

    SAMHSA shall review waiver applications within 45 days of receipt. If approved, NPs and PAs will receive a letter via email that confirms their waiver and includes their prescribing identification number. 

    Qualify

    To qualify for a waiver to treat patients with Opioid Use Disorder, NPs and PAs must:

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain
    • Complete no less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD
    • If required by state law, supervision or working in collaboration with a qualifying physician to prescribe medications for the treatment of OUD may be required.

    Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat OUD before you apply for the waiver.  Some states may have overriding state legislation that will prevent NPs from prescribing these medications even if Federal law allows it.

    Overview of Legislation

    Physicians

    The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies training is necessary for physicians to obtain a waiver to engage in office‐based treatment of opioid use disorders using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, who is one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses.

    Nurse Practitioners & Physician Assistants

    On July 22, 2016, President Obama signed the Comprehensive Addiction and Recovery Act (CARA) into law. CARA authorizes qualified NPs and PAs to become waivered to prescribe buprenorphine in office-based settings for patients with Opioid Use Disorder (OUD) for a five-year period expiring in October 2021.    

    To qualify, NPs and PAs must: 

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain  
    • Complete not less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD  
    • If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD

    HHS' announcement on November 16, 2016, enables NPs and PAs to immediately begin taking the 24 hours of required training. For the full HHS announcement, click here.

    NPs and PAs can begin the training immediately by taking the 8-hour buprenorphine course ASAM currently offers or that other stakeholders offer (see below for more information). The remaining 16 hours will have to be completed with one training provider. ASAM is developing multiple 16-hour training course options and formats, including collaborations with:

    The ASAM Treatment of Opioid Use Disorder Course has been made available in part by an unrestricted educational grant from Indivior, Inc.

  • The ASAM National Practice Guideline 2020 Focused Update Webinar – Adolescents & Young Adults

    Product not yet rated Contains 3 Component(s), Includes Credits Includes a Live Web Event on 09/24/2020 at 1:00 PM (EDT)

    This session will provide an overview of the new and updated recommendations and in-depth information on treating youth with OUD from the ASAM National Practice Guideline.

    image

    The ASAM National Practice Guideline 2020 Focused Update Webinar – Adolescents & Young Adults


    This webinar follows the ASAM National Practice Guideline 2020 Focused Update Fundamentals webinar, which outlines the new and updated recommendations in the 2020 Focused Update of the National Practice Guideline for the Treatment of Opioid Use Disorder

    Adolescents and young adults present for treatment with a broad spectrum of opioid use disorder severity with a range of co-occurring medical and psychiatric illnesses. The treatment of youth with opioid use disorder presents many unique medical, legal, and ethical dilemmas that may complicate treatment. Given these unique issues, adolescents and young adults often benefit from services designed specifically for them. This webinar will provide an overview of the new and updated recommendations and in-depth information on treating youth with OUD from the ASAM National Practice Guideline.

    Session Information 

    Date: Tuesday, September 24, 2020

    Time: 1:00 pm ET / 12:00 pm CT/ 10:00 am PT

    Speaker(s): Marc Fishman, MD

    Learning Objectives 

    By completing this webinar, you will be able to:

    1. Summarize the guideline’s treatment recommendations for adolescents and young adults with OUD and discuss how they should be used in practice. 
    2. Identify the fundamental components of an OUD patient assessment and diagnosis for adolescents and young adults.
    3. Recognize the unique needs and treatment recommendations for adolescents and young adults

    Marc Fishman

    MD

    Marc Fishman MD is a specialist in  addiction psychiatry and addiction medicine.  He is a member of the faculty of the Department of Psychiatry at the Johns Hopkins University School of Medicine. He leads Maryland Treatment Centers, which offers programs for residential and outpatient treatment of drug-involved and dual-diagnosis adolescents and adults. He has written and lectured widely on a variety of topics including youth treatment, placement and treatment matching strategies, co-occurring disorders, and medication treatment for addiction. His research focus has been in treatment of opioid use disorders in youth. Dr. Fishman served as a co-editor for the most recent editions of ASAMs Patient Placement Criteria, leading the adolescent section, and served as the chief editor for the ASAM PPC Supplement on Pharmacotherapies for Alcohol Use Disorders. He is the chair of the Adolescent Committee for ASAM. He is a Past President of the Maryland Society of Addiction Medicine, and a current memeber of its Board.

    ACCME Accredited with Commendation

    CME/CE Credits

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this live internet-based activity for a maximum of 1 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    NAADAC, the Association for Addiction Professionals

    This activity has been approved by the American Society of Addiction Medicine, as a NAADAC Approved Education Provider, for educational credits. NAADAC Provider #295, ASAM is responsible for all aspects of the programming.

    California Association for Drug/Alcohol Educators (CAADE)

    This educational program is approved by CAADE: #CP40 999 1222

    California Association of DUI Treatment Centers (CADTP)

    This educational program is approved by CADTP: #205

    Continuing Education Credits (CEUs)

    Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.

    Maintenance of Certification (MOC)

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1 LLSA credit towards ABPM MOC Part II requirements.

    ABA Maintenance of Certification (MOC)

    This activity contributes to the CME component of the American Board of Anesthesiology’s redesigned Maintenance of Certification in Anesthesiology TM (MOCA®) program, known as MOCA 2.0®.

    ABP Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn a maximum of 1 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.

     ABIM Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    ABAM Transitional Maintenance of Certification (Tmoc)

    Successful completion of this activity can be used to satisfy the American Board of Addiction Medicine (ABAM) for Tmoc as credits towards ABAM LLSA Part II requirements.

    American Board of Psychiatry and Neurology (ABPN)

    Successful completion of this CME activity can be used to satisfy the American Board of Psychiatry and Neurology’s (ABPN) CME requirement for Maintenance of Certification program.

    Program Planning Committee, CME Committee, Medical Education Council (MEC)

    In accordance with disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all CME activities. These policies include resolving all possible conflicts of interest for the Planning Committees, CME Committee, MEC, and Faculty. All activity Planning Committee members and Faculty have disclosed relevant financial relationship information. The ASAM CME Committee has reviewed these disclosures and determined that the relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity. 

    ASAM CME Committee Reviewer

    Subhadeep Barman, MD, FASAM, FAPA - No Financial Disclosures

    Faculty & Planning Committee Disclosures

    Kyle M. Kampman, MD – Does Disclose: World Meds (Clinical Condition: Opioid Use Disorder): Consultant/Advisory Board 

    Marc Fishman, MD – Does Disclose: Alkermes (Clinical Condition: OUD): Consultant/Advisory Board, Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received

    Tricia Wright, MD, MS, DFASAM – Does Disclose McKesson (Clinical Condition: Opioid use in pregnancy): Consultant/Advisory Board

    Sandra Springer, MD – Does Disclose: Alkermes Inc (Clinical Condition: Substance Use Disorder) Consultant/Advisory/Board, reviewed research grants for young investigators Clinical Care Options INc (Clinical Condition: Infectious disease) Speaker/Honoraria (includes speakers bureau, symposia, and expert witness)

    George Woody, MD – Does Disclose: Alkermes Inc (Clinical Condition: Opioid Use Disorder) Consultant/Advisory/Board, Consultant/Advisory Board, Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support) Indivior (Clinical Condition: opioid use disorders) Consultant/Advisory Board, Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support) World Meds (Clinical Condition: Opioid Use Disorders) Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support)

    Daniel Langleben, MD – Does Disclose: Alkermes Inc (Clinical Condition: Opioid Use Disorder) Consultant/Advisory Board 

    Stephen A. Wyatt, DO, FAOAAM, FASAM (Chair) – No Financial Disclosure

    Timothy Wiegand, MD, FACMT, FAACT, DFASAM – No financial Disclosures